DUBLIN--(BUSINESS WIRE)--Sep 4, 2018--The "Global Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market - Segmented by Pipeline Therapeutics, Diagnostic Techniques, Treatment Therapies, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The global nonalcoholic steatohepatitis (NASH) therapeutics and diagnostics market is expected to register a CAGR of 25% during the forecast period of 2018-2023.

Rising Prevalence of Diabetic & Obese Population Globally

The increasing global prevalence of diabetic and obese population particularly in the developed markets is expected to raise the NASH therapeutics and diagnostics market. An estimated 5-20% of the population accounting for nearly 15 million, shows the prevalence of NASH consuming fatty acids diet in the United States, which is driven by obesity and diabetes.

In the United Kingdom, as per the Diabetes Community, 2015, over four million people were diagnosed with diabetes which represented 6% of the United Kingdom's population, i.e., one in every 16. With that, the United Kingdom had the fifth highest rate of obesity in Europe in 2015, with nearly 25% of the population having body mass index of 30 or more. A similar trend or higher could be found in several developed countries, which raises the demand for NASH therapeutics and diagnostics market.

Other factors driving this market are the lucrative pipeline for NASH therapeutics and emergence of novel biomarkers and improvement in liver biopsy technologies.

Other Key Highlights

Slow Advances in the Therapeutic Field & the Lack of Effective Diagnostics for NAFLD North America to Dominate the Market

Notable Developments in the Market

AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis Pharmaceuticals, Inc. for USD 30 million. NorthSea Therapeutics B.V. completed a EUR 25 million Series A funding for the development of icosabutate, an oral promising drug candidate for the treatment of NASH.

Companies Profiled

AstraZeneca PLC Conatus Pharmaceuticals Inc. Enzo Biochem Inc. Galmed Pharmaceuticals Ltd. Genfit Corp. Gilead Horizon Pharma PLC Immuron Intercept Pharmaceuticals Inc. Novo Nordisk A/S

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Market Dynamics

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/qxzc3p/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180904005404/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diagnostics,Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/04/2018 06:58 AM/DISC: 09/04/2018 06:58 AM